Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Ecs-Progastrin SA maintains a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The data shows 1 pending office action currently active. This workload is handled by the distinct examiner, indicating that prosecution is currently concentrated in a single channel at the USPTO. This arrangement provides the applicant with a clear and singular focus for their legal strategy.
The busiest examiner for this portfolio is GODDARD, LAURA B, who is responsible for the pending office action. Since the total number of pending office actions is 1, this examiner manages the entire active workload. This creates a singular focus for the applicant, as the progress of the portfolio depends on the interactions with this specific individual and the feedback from GODDARD, LAURA B.
Furthermore, the prosecution is limited to 1 distinct art unit. This suggests that the technical scope of the pending intellectual property is currently confined to one specialized area of Biotechnology & Pharmaceuticals. For a practitioner, the presence of only 1 distinct art unit simplifies the management of the portfolio, as there is no need to coordinate between different examination groups.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GODDARD, LAURA B | 1 | 50.9% | +13.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16975271 | PROGASTRIN AS A BIOMARKER FOR IMMUNOTHERAPY | GODDARD, LAURA B | 81d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16975271 | PROGASTRIN AS A BIOMARKER FOR IMMUNOTHERAPY | GODDARD, LAURA B | 81d overdue |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 16975271 | PROGASTRIN AS A BIOMARKER FOR IMMUNOTHERAPY | GODDARD, LAURA B | 1642 | §101§103§112 | Non-Final OA | 81d overdue | Pending | Aug 24, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial